1 mutation in 100 000 wild-types because sensitivity matters
Rarity superRCA is an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples like liquid biopsies. The format and flexibility of the technology platform – and read-out based on flow cytometry – makes it suitable for research as well as clinical application.
Rarity offers ultrasensitive superRCA® assays for research, available for service testing. The superRCA® assays are designed for extreme sensitivity to enable the full potential of liquid biopsy.
superRCA is an ultra-sensitive and highly specific molecular amplification technology. It is used to detect very small amounts of DNA sequence variants, like cancer mutations, in patient tissue or Liquid Biopsies.
It offers effective detection of multiple targets simultaneously – so called multiplexing. The assay can be performed in most hematology laboratories with existing equipment, using well-established flow cytometry for read-out, enabling more accessible testing with shorter response times.
Rarity Biosciences was founded in 2021 as a spin out from Uppsala University to further develop and commercialize the superRCA assay technology. The superRCA technology was first discovered and developed by PhD Lei Chen and Professor Ulf Landegren in the Molecular Tools group at the Department of Immunology, Genetics, and Pathology.
Want to know more about our history of research and our different methods?
To further accelerate growth, Rarity Bioscience announces today a new strategicinvestment from Belgium based Novalis Biotech. The investment is facilitated
With the aim to improve cancer diagnostics, Rarity Bioscience has raised €2,5 million to expand operations and product development within
During November, Rarity Bioscience offer free analysis of liquid biopsy samples for cancer research. Movember is a month-long event to
Ultrasensitive and reliable
10-100 times more sensitive than current technologies, detecting down 1 mutation in 100,000
Multiplex but simple
Analyse on up to 100 targets from the same DNA sample, with uncompromised sensitivity using the superRCA multiplex
Fast & cost-efficient
Read-out using flow cytometry enables patient-near testing on existing equipment for fast and cost-efficient testing
Sitemap
Contact us
